Voriconazole dosage and administration: Difference between revisions
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Voriconazole}} {{CMG}}; {{AE}} {{AZ}} ==Dosage and Administration== ===Instructions for Use in All Patients=== VFEND Tablets or Oral Suspension should be taken ..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 17: | Line 17: | ||
Blood products and concentrated electrolytes | Blood products and concentrated electrolytes | ||
VFEND I.V. must not be infused concomitantly with any blood product or short-term infusion of concentrated electrolytes, even if the two infusions are running in separate intravenous lines (or cannulas). Electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia should be corrected prior to initiation of VFEND therapy | VFEND I.V. must not be infused concomitantly with any blood product or short-term infusion of concentrated electrolytes, even if the two infusions are running in separate intravenous lines (or cannulas). Electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia should be corrected prior to initiation of VFEND therapy . | ||
Intravenous solutions containing (non-concentrated) electrolytes | Intravenous solutions containing (non-concentrated) electrolytes | ||
| Line 31: | Line 31: | ||
*:'''Invasive aspergillosis''' and serious fungal infections due to Fusarium spp. and Scedosporium apiospermum | *:'''Invasive aspergillosis''' and serious fungal infections due to Fusarium spp. and Scedosporium apiospermum | ||
See Table 1. Therapy must be initiated with the specified loading dose regimen of intravenous VFEND on Day 1 followed by the recommended maintenance dose regimen. Intravenous treatment should be continued for at least 7 days. Once the patient has clinically improved and can tolerate medication given by mouth, the oral tablet form or oral suspension form of VFEND may be utilized. The recommended oral maintenance dose of 200 mg achieves a voriconazole exposure similar to 3 mg/kg IV; a 300 mg oral dose achieves an exposure similar to 4 mg/kg IV. Switching between the intravenous and oral formulations is appropriate because of the high bioavailability of the oral formulation in adults [ | See Table 1. Therapy must be initiated with the specified loading dose regimen of intravenous VFEND on Day 1 followed by the recommended maintenance dose regimen. Intravenous treatment should be continued for at least 7 days. Once the patient has clinically improved and can tolerate medication given by mouth, the oral tablet form or oral suspension form of VFEND may be utilized. The recommended oral maintenance dose of 200 mg achieves a voriconazole exposure similar to 3 mg/kg IV; a 300 mg oral dose achieves an exposure similar to 4 mg/kg IV. Switching between the intravenous and oral formulations is appropriate because of the high bioavailability of the oral formulation in adults. | ||
{| | |||
|[[File:Table1dosing.JPG|900px|thumb]] | |||
|} | |||
*:'''Candidemia''' in non-neutropenic patients and other deep tissue Candida infections | *:'''Candidemia''' in non-neutropenic patients and other deep tissue Candida infections | ||
See Table 1. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer. | See Table 1. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer. | ||
{| | |||
|[[File:Table1dosing.JPG|900px|thumb]] | |||
|} | |||
*:'''Esophageal Candidiasis''' | *:'''Esophageal Candidiasis''' | ||
See Table 1. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VFEND (VORICONAZOLE) TABLET, FILM COATED VFEND (VORICONAZOLE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION VFEND (VORICONAZOLE) POWDER, FOR SUSPENSION [ROERIG] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce3ef5cf-3087-4d92-9d94-9eb8287228db | publisher = | date = | accessdate = }}</ref> | See Table 1. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VFEND (VORICONAZOLE) TABLET, FILM COATED VFEND (VORICONAZOLE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION VFEND (VORICONAZOLE) POWDER, FOR SUSPENSION [ROERIG] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce3ef5cf-3087-4d92-9d94-9eb8287228db | publisher = | date = | accessdate = }}</ref> | ||
{| | |||
|[[File:Table1dosing.JPG|900px|thumb]] | |||
|} | |||
==References== | ==References== | ||
Latest revision as of 07:55, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Dosage and Administration
Instructions for Use in All Patients
VFEND Tablets or Oral Suspension should be taken at least one hour before or after a meal.
VFEND I.V. for Injection requires reconstitution to 10 mg/mL and subsequent dilution to 5 mg/mL or less prior to administration as an infusion, at a maximum rate of 3 mg/kg per hour over 1 to 2 hours.
Do not administer as an IV bolus injection.
Use of VFEND I.V. With Other Parenteral Drug Products
Blood products and concentrated electrolytes
VFEND I.V. must not be infused concomitantly with any blood product or short-term infusion of concentrated electrolytes, even if the two infusions are running in separate intravenous lines (or cannulas). Electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia should be corrected prior to initiation of VFEND therapy .
Intravenous solutions containing (non-concentrated) electrolytes
VFEND I.V. can be infused at the same time as other intravenous solutions containing (non-concentrated) electrolytes, but must be infused through a separate line.
Total parenteral nutrition (TPN)
VFEND I.V. can be infused at the same time as total parenteral nutrition, but must be infused in a separate line. If infused through a multiple-lumen catheter, TPN needs to be administered using a different port from the one used for VFEND I.V.
Recommended Dosing in Adults
- Invasive aspergillosis and serious fungal infections due to Fusarium spp. and Scedosporium apiospermum
See Table 1. Therapy must be initiated with the specified loading dose regimen of intravenous VFEND on Day 1 followed by the recommended maintenance dose regimen. Intravenous treatment should be continued for at least 7 days. Once the patient has clinically improved and can tolerate medication given by mouth, the oral tablet form or oral suspension form of VFEND may be utilized. The recommended oral maintenance dose of 200 mg achieves a voriconazole exposure similar to 3 mg/kg IV; a 300 mg oral dose achieves an exposure similar to 4 mg/kg IV. Switching between the intravenous and oral formulations is appropriate because of the high bioavailability of the oral formulation in adults.
 |
- Candidemia in non-neutropenic patients and other deep tissue Candida infections
See Table 1. Patients should be treated for at least 14 days following resolution of symptoms or following last positive culture, whichever is longer.
|
- Esophageal Candidiasis
See Table 1. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.[1]
|
References
Adapted from the FDA Package Insert.